Europe Allows Derogation of Atypical Actives from ICH Q7
This article was originally published in The Gold Sheet
Executive Summary
The European Medicines Agency tackled the issue of atypical actives in 2008, David Cockburn, head of manufacturing quality compliance at EMA, told a recent PDA workshop in Bethesda, Md.